JP2024509269A5 - - Google Patents
Info
- Publication number
- JP2024509269A5 JP2024509269A5 JP2023555290A JP2023555290A JP2024509269A5 JP 2024509269 A5 JP2024509269 A5 JP 2024509269A5 JP 2023555290 A JP2023555290 A JP 2023555290A JP 2023555290 A JP2023555290 A JP 2023555290A JP 2024509269 A5 JP2024509269 A5 JP 2024509269A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- pharmaceutical composition
- nras
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158798P | 2021-03-09 | 2021-03-09 | |
| US63/158,798 | 2021-03-09 | ||
| PCT/US2022/019273 WO2022192202A1 (en) | 2021-03-09 | 2022-03-08 | Belvarafenib for use in treatment of brain cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509269A JP2024509269A (ja) | 2024-02-29 |
| JP2024509269A5 true JP2024509269A5 (https=) | 2025-03-17 |
Family
ID=80952247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555290A Pending JP2024509269A (ja) | 2021-03-09 | 2022-03-08 | 脳がんの治療における使用のためのベルバラフェニブ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240173329A1 (https=) |
| EP (1) | EP4304592A1 (https=) |
| JP (1) | JP2024509269A (https=) |
| KR (1) | KR20230156731A (https=) |
| CN (1) | CN117940130A (https=) |
| TW (1) | TW202300151A (https=) |
| WO (1) | WO2022192202A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| BR112014015720B1 (pt) | 2011-12-30 | 2020-03-17 | Hanmi Pharm. Co., Ltd. | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
| KR20190057421A (ko) | 2012-08-17 | 2019-05-28 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| KR102204520B1 (ko) | 2012-10-12 | 2021-01-20 | 엑셀리시스, 인코포레이티드 | 암의 치료에 사용하기 위한 화합물의 신규 제조 방법 |
| EP3624896A4 (en) * | 2017-05-16 | 2021-03-31 | Biomed Valley Discoveries, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS |
| IL274969B2 (en) * | 2017-11-30 | 2026-03-01 | Hanmi Pharmaceutical Co Ltd | Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[2,3-D]pyrimidine-7-carboxamide, and crystalline forms thereof |
| EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| CA3178927A1 (en) * | 2020-05-26 | 2021-12-02 | Hanmi Pharm. Co., Ltd. | Belvarafenib for use in cancer treatment |
-
2022
- 2022-03-08 CN CN202280019974.7A patent/CN117940130A/zh active Pending
- 2022-03-08 WO PCT/US2022/019273 patent/WO2022192202A1/en not_active Ceased
- 2022-03-08 EP EP22713146.3A patent/EP4304592A1/en active Pending
- 2022-03-08 US US18/549,622 patent/US20240173329A1/en active Pending
- 2022-03-08 JP JP2023555290A patent/JP2024509269A/ja active Pending
- 2022-03-08 KR KR1020237033790A patent/KR20230156731A/ko active Pending
- 2022-03-09 TW TW111108545A patent/TW202300151A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4729503B2 (ja) | 抗癌剤の奏効率増強剤 | |
| Lee et al. | Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma | |
| JP2017516784A5 (https=) | ||
| RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
| JP2020514311A5 (https=) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2017505321A5 (https=) | ||
| JP2020519672A5 (https=) | ||
| JP2023530351A5 (https=) | ||
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2017526662A5 (https=) | ||
| JP2023505056A5 (https=) | ||
| JP2023088996A5 (https=) | ||
| CA2360228A1 (en) | Treatment of tumor metastases and cancer | |
| Jin et al. | Rational targeting of autophagy in colorectal cancer therapy: From molecular interactions to pharmacological compounds | |
| JP2024509269A5 (https=) | ||
| Arnott | The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma | |
| JP2016502540A5 (https=) | ||
| JP2022537453A5 (https=) | ||
| Song et al. | Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors | |
| JP2023515687A5 (https=) | ||
| JP2022542524A5 (https=) | ||
| JP2025513929A5 (https=) |